LY01008

Monoclonal antibody

Phase 3 · investigational in the USVEGF-ANo recent registered activity
Approvedregulatory verdict

Evidence outlook

Approved: Advanced, metastatic or recurrent non-small-cell lung cancer and metastatic colorectal... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also approved (1)
CN
  • Advanced, metastatic or recurrent non-small-cell lung cancer and metastatic colorectal cancer (Boyounuo, bevacizumab biosimilar)
Product first approved 2021luye.cn

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Non-Small Cell Lung Cancer
Phase 1 (1)
Non-Small Cell Lung Cancer
NCT05110118 · Shandong Boan Biotechnology Co., Ltd
2020-08-04 – 2021-01-13 · Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
What this study did

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, 20 of them ahead of this one.

This drug's own stage for Colorectal Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
LY01008: this drugPhase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)
Approved(overall)
Protein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Abzv (Enzeevu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Boav (Eydenzelt)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Brolucizumab-Dbll
Approved(overall)
Antibody fragmentVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
Ranibizumab (Lucentis)
Approved(overall)
Antibody fragmentVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BAT5906
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
CKD-701 (Lucenbies)
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
HLX04-O
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)
Phase 3(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Surabgene Lomparvovec
Phase 3(overall)
Gene therapy / editingVEGF-A
Weak signal(overall)
No reviewed efficacy summary in this indication
Tarcocimab Tedromer
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
MW02
Phase 2/3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)
Phase 1(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Telbermin
Discontinued
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.